Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches

E-ISSN： 1873-5576|7|6|541-558

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.7, Iss.6, 2007-09, pp. : 541-558

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Biospecific Agents for the Treatment of Myelodysplastic Syndromes

By Gotlib Jason Greenberg Peter L.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 1, Iss. 4, 2003-11 ,pp. : 473-480

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Lenalidomide for Treatment of Myelodysplastic Syndromes

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3198-3203

Bentham Science Publishers

Access to resources Recommend Favorite

5-Azacytidine for the treatment of myelodysplastic syndromes

By Krawczyk Janusz Keane Niamh Freeman Ciara Louise Swords Ronan O'Dwyer Michael Giles Francis J

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 9, 2013-06 ,pp. : 1255-1268

Informa Healthcare

Access to resources Recommend Favorite

Arsenic trioxide for the treatment of myelodysplastic syndromes

By Vey Norbert

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 3, 2004-03 ,pp. : 613-621

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic spectrum in the treatment of myelodysplastic syndromes

By Hofmann Wolf-K Baldus Claudia Uharek Lutz Thiel Eckhard

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 12, 2004-12 ,pp. : 2451-2458

Informa Healthcare

Access to resources Recommend Favorite